Show simple item record

dc.contributor.authorSiveke, J
dc.contributor.authorCubillo, A
dc.contributor.authorBlanc, J
dc.contributor.authorMelisi, D
dc.contributor.authorVon Hoff, D
dc.contributor.authorWang-Gillam, A
dc.contributor.authorChen, L
dc.contributor.authorBecker, C
dc.contributor.authorMamlouk, K
dc.contributor.authorBelanger, B
dc.contributor.authorYang, Y
dc.contributor.authorde Jong, F
dc.contributor.authorHubner, Richard A
dc.date.accessioned2016-12-16T15:43:57Z
dc.date.available2016-12-16T15:43:57Z
dc.date.issued2016
dc.identifier.citationEffects of nanoliposomal irinotecan (nal-IRI;MM-398) 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy. 2016, 39: 259-259 Oncol Res Treaten
dc.identifier.urihttp://hdl.handle.net/10541/620053
dc.language.isoenen
dc.titleEffects of nanoliposomal irinotecan (nal-IRI;MM-398) 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentWest German Cancer Centre, University Hospital Essen, Essen, Germanyen
dc.identifier.journalOncology Research and Treatmenten


This item appears in the following Collection(s)

Show simple item record